Lyell Immunopharma (LYEL) Asset Utilization Ratio (2021 - 2026)
Lyell Immunopharma recorded quarterly Asset Utilization Ratio of 0.0 in Q1 2026, down 6.74% quarter-over-quarter from 0.0 in Q4 2025, and down 36.43% year-over-year from 0.0 in Q1 2025.
Lyell Immunopharma's Asset Utilization Ratio history runs 6 years deep, the most recent figure standing at 0.0 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 36.43% year-over-year to 0.0; the TTM figure through Mar 2026 stood at 0.0 (down 36.43% YoY), while the FY2025 annual figure was 0.0, down 11.86% from the prior year.
- Asset Utilization Ratio came in at 0.0 for Q1 2026 at Lyell Immunopharma, down from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.09 in Q1 2023 to a low of 0.0 in Q2 2024.
- A 5-year average of 0.02 and a median of 0.0 in 2025 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio jumped 1063.08% in 2023 and sank 99.9% in 2024, its largest moves.
- Lyell Immunopharma's Asset Utilization Ratio stood at 0.09 in 2022, then plunged by 99.81% to 0.0 in 2023, then plunged by 34.69% to 0.0 in 2024, then dropped by 12.42% to 0.0 in 2025, then decreased by 6.74% to 0.0 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.85 |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.06 |
| Jun 30, 2023 | 0.06 |
| Mar 31, 2023 | 0.09 |
| Dec 31, 2022 | 0.09 |
| Sep 30, 2022 | 0.04 |
| Jun 30, 2022 | 0.04 |
| Mar 31, 2022 | 0.01 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | 0.01 |